
Enhanced BCMA – CAR T-cell therapeutic efficacy in multiple myeloma
Chimeric antigen-specific receptor (CAR) T-cell immunotherapy targeting B-cell maturation antigen (BCMA; BCMA-CAR T cells) has produced remarkable clinical responses in advanced multiple myeloma (MM), with a substantial fraction of patients achieving complete remission . However, many patients relapse within months […]













